Month: December 2020

PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae


Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of its global, Phase 2 trial of LYT-100 (deupirfenidone) in Long COVID respiratory complications and related sequelae. LYT-100…

Read More

Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)


Excerpt from the Press Release: PRINCETON, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it has submitted to the U.S. Food and Drug Administration (FDA) a protocol to…

Read More

How nanotechnology helps mRNA Covid-19 vaccines work


Excerpt from the Article: While the first two Covid-19 vaccines relying on messenger RNA technology speed toward regulatory approval in the U.S., it’s worth remembering the vehicle that gets them where they need to go in the body. Lipid nanoparticles are the fatty molecular envelopes that help strands of mRNA — the genetic messenger for…

Read More

TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma


Excerpt from the Press Release: BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) — TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for the preservative free multi-dose delivery of a proprietary Latanoprost formulation, including the clinical study…

Read More

MapLight Therapeutics Announces Completion of Dosing in Phase 1 Study of Therapy for Social Deficit in Autism Spectrum Disorder


Excerpt from the Press Release: SAN FRANCISCO, Nov. 23, 2020 /PRNewswire/ — MapLight Therapeutics today announced it has completed dosing of healthy volunteers across five cohorts in a Phase 1 clinical trial evaluating the safety of ML-004, a selective serotonin receptor agonist. Based on results from the study to date, ML-004, which MapLight intends to evaluate…

Read More

Persephone Biosciences Initiates the ARGONAUT Study of Gut Microbiome-Linked Immune Modulation in Cancer Treatment Response


Excerpt from the Press Release: SAN DIEGO, Nov. 23, 2020 /PRNewswire/ — Persephone Biosciences Inc., a biotechnology company that leverages real world data and artificial intelligence to design microbiome therapeutics and diagnostics to promote normal immune function and fight disease, today announced the initiation of the ARGONAUT clinical study to determine the impact of gut microbiome…

Read More

BigBio Communications Launches The BioCalendar, The Premier Industry Calendar for Life Science Conferences and Events


Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–BigBio Communications, developer of the life science industry news aggregator Big4Bio, proudly announces the launch of The BioCalendar (, an exclusive event listing platform for the global healthcare and biopharmaceutical industry. The BioCalendar was created to be the comprehensive calendar and guide for healthcare and life science industry…

Read More

CASTL supports life sciences students and industry growth with Financial Award program


Excerpt from the Article: Charlottetown, PE – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced today Financial Awards of $5,000 for 32 post-secondary students across Atlantic Canada to support their academic studies in life sciences. This Financial Award program will support life sciences students enrolled in co-operative education from Acadia University, Université…

Read More

Common Anti-Inflammatory Drug Added to COVID-19 Treatment Study


Excerpt from the Press Release: United Kingdom (Precision Vaccinations) A commonly used anti-inflammatory treatment has been added to the Randomised Evaluation of COVid-19 thERapY (RECOVERY) study, the world’s largest clinical trial of treatments for patients hospitalized with COVID-19. Professor Peter Horby at the University of Oxford and co-Chief Investigator of the RECOVERY trial, said in…

Read More

Pfizer Covid Vaccine Faces Hurdles After FDA Filing Friday


Excerpt from the Article: Pfizer Inc. and BioNTech SE requested emergency authorization of their Covid vaccine on Friday, and it could take at least three weeks for a U.S. Food and Drug Administration decision as trial data is probed by agency staff and outside advisers. Shown to be 95 percent effective and without any major…

Read More